Xtant TM Medical Announces Expanded Patent Coverage of Core Technologies

XtantTM Medical Announces Expanded

Patent Coverage of Core Technologies

Mont., September 22, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of

regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, Bacterin International,

Inc., has received notification that the United States Patent and Trademark Office has issued US Patent No. 9,114,191

entitled "Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors." The patent

covers demineralized bone matrices derived from cortical bone, which include Bacterin's branded product lines OsteoSTX ,

OsteoWrap , and OrbitalWrap HD. Bacterin has pending patent applications in the United States to pursue protection

on other aspects of its allograft processing and demineralization technologies.

"The issuance of this patent

confirms Bacterin's position as a leader in allograft processing innovation," said Dr. Gregory Juda, Bacterin's

Chief Scientific Officer. "This patent adds to the growing body of evidence substantiating the superior processing methodologies

associated with Bacterin's allograft portfolio."

Bacterin's patented processing

technologies impart ideal handling properties to allografts while simultaneously exposing native growth factors that are inherent

to natural human bone. The resulting enhanced biologic activity promotes rapid healing via tissue regeneration for patients requiring

bone-grafting procedures. Taking advantage of this unique combination of properties, clinical investigators evaluating Bacterin's

patented demineralized bone grafts have demonstrated fusion rates greater than 97 percent in peer-reviewed, published studies.

About Xtant Medical Holdings

Xtant Medical Holdings,

Inc. (OTCQX:BONE) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international

markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion

of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic

disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic

and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic

surgery markets. For further information, please visit www.xtantmedical.com.

Important Cautions Regarding

Forward-looking Statements

This press release contains certain

disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive

in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts,"

"expects," "anticipates," "intends," "plans," "believes," "estimates,"

"projects," "forecasts," "strategy," "will," "goal," "target," "prospects,"

"potential," "optimistic," "confident," "likely," "probable" or similar expressions

or the negative thereof.

Statements of historical fact also

may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,

and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability

to successfully integrate the acquisition of X-spine; the ability of the Company's sales force to achieve expected results; the

Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations

contained in the Company's secured lending facility; the Company's ability to manage cash flow; the Company's ability to develop,

market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability

of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed;

changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate

skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment,

including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form

10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release

publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect

the occurrence of unanticipated events, except as required by law.